Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial
- PMID: 17761995
- PMCID: PMC1971192
- DOI: 10.1136/bmj.39303.723449.55
Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial
Abstract
Objective: To quantify the psychological impact of primary care based stepwise screening for type 2 diabetes.
Design: Controlled trial and comparative study embedded in a randomised controlled trial.
Setting: 15 practices (10 screening, five control) in the ADDITION (Cambridge) trial in the east of England.
Participants: 7380 adults (aged 40-69) in the top fourth for risk of having undiagnosed type 2 diabetes (6416 invited for screening, 964 controls).
Interventions: Invited for screening for type 2 diabetes or not invited (controls), incorporating a comparative study of subgroups of screening attenders. Attenders completed questionnaires after a random blood glucose test and at 3-6 months and 12-15 months later. Controls were sent questionnaires at corresponding time points. Non-attenders were sent questionnaires at 3-6 months and 12-15 months.
Main outcome measures: State anxiety (Spielberger state anxiety inventory), anxiety and depression (hospital anxiety and depression scale), worry about diabetes, and self rated health.
Results: No significant differences were found between the screening and control participants at any time-for example, difference in means (95% confidence intervals) for state anxiety after the initial blood glucose test was -0.53, -2.60 to 1.54, at 3-6 months was 1.51 (-0.17 to 3.20), and at 12-15 months was 0.57, -1.11 to 2.24. After the initial test, compared with participants who screened negative, those who screened positive reported significantly poorer general health (difference in means -0.19, -0.25 to -0.13), higher state anxiety (0.93, -0.02 to 1.88), higher depression (0.32, 0.08 to 0.56), and higher worry about diabetes (0.25, 0.09 to 0.41), although effect sizes were small. Small but significant trends were found for self rated health across the screening subgroups at 3-6 months (P=0.047) and for worry about diabetes across the screen negative groups at 3-6 months and 12-15 months (P=0.001).
Conclusions: Screening for type 2 diabetes has limited psychological impact on patients. Implementing a national screening programme based on the stepwise screening procedure used in the ADDITION (Cambridge) trial is unlikely to have significant consequences for patients' psychological health.
Trial registration: Current Controlled Trials ISRCTN99175498 [controlled-trials.com].
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Screening for diabetes.BMJ. 2007 Sep 8;335(7618):457-8. doi: 10.1136/bmj.39323.395336.BE. Epub 2007 Aug 30. BMJ. 2007. PMID: 17761997 Free PMC article.
Similar articles
-
Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Aug. Report No.: 21-05276-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Aug. Report No.: 21-05276-EF-1. PMID: 34554661 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. PMID: 32129963 Free Books & Documents. Review.
-
Predictors of anxiety and depression among people attending diabetes screening: a prospective cohort study embedded in the ADDITION (Cambridge) randomized control trial.Br J Health Psychol. 2011 Feb;16(Pt 1):213-26. doi: 10.1348/135910710X495366. Br J Health Psychol. 2011. PMID: 21226792 Clinical Trial.
-
Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial.BMJ. 2009 Nov 30;339:b4535. doi: 10.1136/bmj.b4535. BMJ. 2009. PMID: 19948642 Free PMC article. Clinical Trial.
-
Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice.BMC Public Health. 2008 Oct 7;8:350. doi: 10.1186/1471-2458-8-350. BMC Public Health. 2008. PMID: 18840266 Free PMC article. Clinical Trial.
Cited by
-
Recurrent SARS-CoV-2 Serology Testing and Pandemic Anxiety: A Study of Pediatric Healthcare Workers.Int J Environ Res Public Health. 2022 Aug 3;19(15):9562. doi: 10.3390/ijerph19159562. Int J Environ Res Public Health. 2022. PMID: 35954913 Free PMC article.
-
Screening for Diabetes and Prediabetes.Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385. doi: 10.1016/j.ecl.2021.05.002. Epub 2021 Jul 12. Endocrinol Metab Clin North Am. 2021. PMID: 34399951 Free PMC article. Review.
-
Effect of SARS-CoV-2 antibody screening on participants' attitudes and behaviour: a study of industry workers in Split, Croatia.Public Health. 2021 Feb;191:11-16. doi: 10.1016/j.puhe.2020.12.001. Epub 2020 Dec 7. Public Health. 2021. PMID: 33465515 Free PMC article.
-
Screening for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2020 May 29;5(5):CD005266. doi: 10.1002/14651858.CD005266.pub2. Cochrane Database Syst Rev. 2020. PMID: 32470201 Free PMC article.
-
Patients' and practice nurses' perceptions of depression in patients with type 2 diabetes and/or coronary heart disease screened for subthreshold depression.BMC Fam Pract. 2018 Dec 23;19(1):202. doi: 10.1186/s12875-018-0870-y. BMC Fam Pract. 2018. PMID: 30579329 Free PMC article.